Co-crystals of finerenone, pecavaptan, and sglt2 inhibitors

CA3328192A1Undetermined Publication Date: 2025-10-30BAYER AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CA3328192
Authority / Receiving Office
CA · CA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-04-22
Filing Date
2025-04-22
Publication Date
2025-10-30
Patent Text Reader

Abstract

The invention refers to a co-crystal according to any one of formulae (I), (II), (III), (IV), (V), (VI) and / or (VII). Furthermore, the invention refers to a pharmaceutical formulation comprising any one of co-crystals according to formulae (I), (II), (III), (IV), (V), (VI) and / or (VII), the medical use of these co-crystals or the pharmaceutical formulation comprising such co-crystal(s) as well as to a process for preparing these co- crystals. The invention further refers to crystalline forms of and / or Empagliflozin as well as pharmaceutical comprising such crystalline forms.
Need to check novelty before this filing date? Find Prior Art